IMMUNOHUB

IMMUNO-HUB is a national research platform for the development of biopharmaceuticals and immunotherapies, designed to accelerate responses to infectious and tumour diseases through coordinated academic and clinical research.

Role of our laboratory

Recombinant protein production and structural, biophysical and analytical characterization of SARS-CoV-2 targets, and coordination of the work package focusing on development of innovative vaccines against COVID-19.

Project details

• Full title: Immunotherapy: treatment and prevention of infectious and tumour diseases
• Funding agency: Ministero della Salute
• Programme: Piano Operativo Salute – Traiettoria 4
• Project code: IMMUNO-HUB
• Total project funding: EUR 7’000’000.00 (funding to the laboratory: EUR 166’200.00)
• Project period: 13 February 2023 – 31 December 2028 (with granted extension)
• Institutions involved: University of Pavia (Italy, Coordinator), University of Rome Tor Vergata (Italy), University of Insubria (Italy), Fondazione IRCCS Policlinico San Matteo (Italy), ASST Fatebenefratelli Sacco (Italy), Fondazione IRCCS Istituto Nazionale dei Tumori (INT, Italy), Scuola Normale Superiore (Italy)

Co-Investigator / Work Package Coordinator

Federico Forneris

Permanent Staff – Armenise-Harvard Laboratory

Former Lab Members Involved

Francesca Magnani

Lab Alumni – Armenise-Harvard Laboratory